Conference
Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
Authors
Le Tourneau C; Winquist E; Hotte SJ; Laurie SA; Soulieres D; Chia SK; Singh S; Wang T; Mormont C; Siu LL
Volume
28
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
May 20, 2010
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X